# US 2019/0316207 A1 · Mir-320e and colorectal cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316207 A1
- Document ID: US20190316207A1
- Status: Published application
- Kind: A1
- Application number: 16/372,747
- Filed: 2019-04-02
- Published: 2019-10-17
- Earliest claimed: 2014-02-18
- Assignees: Baylor Research Institute
- Applicants: Baylor Research Institute
- Inventors: Ajay Goel; Lucia Perez-Carbonell; C. Richard Boland
- Web page: https://patentgrep.com/patent/US20190316207A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- G16H 10/60: for patient-specific data, e.g. for electronic patient records
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 40/63: for local operation
- G16H 50/30: for calculating health indices; for individual health risk assessment
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/30: Special therapeutic applications
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Embodiments provide methods and compositions related to determining treatments for colorectal cancer patients by detection and analysis of the expression level of miRNA such as miR-320e in the patients.

## Claims

### Claim at position 1

1-40. (canceled)

### Claim 41

A method for treating a patient with colorectal cancer comprising administering a treatment to the patient that inhibits the expression of miR-320e, wherein a sample from the patient is determined to have an increased expression level in a gene encoding miR-320e compared to a control or reference expression level for the gene.

### Claim at position 3

42-51. (canceled)

### Claim 52 (depends on 41)

The method of claim 41, wherein the sample from the patient comprises a tissue sample, a whole blood sample, a urine sample, a saliva sample, a serum sample or a fecal sample.

### Claim 53 (depends on 41)

The method of claim 41, wherein the sample is a tissue sample.

### Claim 54 (depends on 41)

The method of claim 41, wherein the sample is a rectum sample, a colon sample or a cecum sample.

### Claim 55 (depends on 54)

The method of claim 54, wherein the sample is a rectum sample.

### Claim 56 (depends on 41)

The method of claim 41, wherein the sample is a fresh sample, frozen sample, preserved sample, formalin-fixed, paraffin-embedded (FFPE) sample, or a fine needle aspirate.

### Claim 57 (depends on 41)

The method of claim 41, wherein the cancer is stage II or III colorectal cancer.

### Claim 58 (depends on 41)

The method of claim 41, wherein the cancer is stage IV colorectal cancer.

### Claim 59

A method of detecting the expression level of miR-320e in a human subject diagnosed with colorectal cancer and selecting a treatment for a human subject diagnosed with colorectal cancer, the method comprising:
a.) assaying nucleic acids obtained from a biological sample from the human subject to determine a first expression level of miR-320e in the biological sample from the human subject; and
b.) comparing the first expression level of miR-320e in the biological sample from the human subject to a reference expression level of miR-320e indicative of recurrent colorectal cancer; or
comparing the first expression level of miR-320e in the biological sample from the human subject to a reference expression level of miR-320e indicative of non-recurrent colorectal cancer.

### Claim 60 (depends on 59)

The method of claim 59, wherein the sample from the patient comprises a tissue sample, a whole blood sample, a urine sample, a saliva sample, a serum sample or a fecal sample.

### Claim 61 (depends on 59)

The method of claim 59, wherein the biological sample from the human subject comprises a tissue sample.

### Claim 62 (depends on 59)

The method of claim 59, wherein the biological sample from the human subject comprises a rectum sample, a colon sample or a cecum sample.

### Claim 63 (depends on 59)

The method of claim 59, wherein the biological sample from the human subject comprises is a rectum sample.

### Claim 64 (depends on 59)

The method of claim 59, wherein the biological sample from the human subject comprises a fresh sample, frozen sample, preserved sample, formalin-fixed, paraffin-embedded (FFPE) sample, or a fine needle aspirate.

### Claim 65 (depends on 59)

The method of claim 59, wherein assaying nucleic acids comprises the use of a microarray, PCR, digital PCR, dd PCR (digital droplet PCR), nCounter, BEAMing (Beads, Emulsions, Amplifications, and Magnetics), ARMS (Amplification Refractory Mutation Systems), RNA-Seq, TAm-Seg (Tagged-Amplicon deep sequencing), PAP (Pyrophosphorolysis-activation polymerization), RT-PCR, in situ hybridization, northern hybridization, hybridization protection assay (HPA), branched DNA (bDNA) assay, rolling circle amplification (RCA), single molecule hybridization detection, Invader assay, and/or Bridge Litigation Assay, next generation RNA sequencing, or a combination thereof.

### Claim 66 (depends on 59)

The method of claim 59, wherein the method comprises comparing the first expression level of miR-320e in the biological sample from the human subject to a reference expression level of miR-320e indicative of recurrent colorectal cancer.

### Claim 67 (depends on 59)

The method of claim 59, wherein the method comprises comparing the first expression level of miR-320e in the biological sample from the human subject to a reference expression level of miR-320e indicative of non-recurrent colorectal cancer.

### Claim 68 (depends on 66)

The method of claim 66, wherein the first expression level of miR-320e in the biological sample from the human subject is determined to be decreased compared to the reference level of expression.

### Claim 69 (depends on 67)

The method of claim 67, wherein the first expression level of miR-320e in the biological sample from the human subject is determined to be not significantly different than the reference level of expression.

### Claim 70 (depends on 59)

The method of claim 59, wherein the method further comprises isolating nucleic acids from a biological sample from the patient.
